Breast Cancer

Breast Cancer

Substantial investment in breast cancer research has led to advances in screening, treatment, and prevention over the last four decades. As a result, over 90 percent of breast cancers are diagnosed at an early age, surgery has become less invasive, and the development of more effective therapies have boosted cure rates to current highs. Crucial insights from genetics research have also led to new, preventive drugs and surgeries that have helped to reduce the risk of occurrence for women who are at high risk for the disease, including those predisposed as a result of genetic mutations.

Today, nine out of ten women are alive five years after diagnosis and mortality has fallen by more than a third since the 1980s. However, more research is still needed to develop better treatments for advanced stages and currently resistant forms of breast cancer, and to address profound racial disparities in breast cancer mortality. 

Expand All +

1941

Ovarian and hormone suppression found to improve breast cancer outcomes

Ovarian and hormone suppression found to improve breast cancer outcomes

Researchers establish that ovarian function and hormone production have a significant impact on breast cancer treatment outcomes in pre-menopausal women. They find that various approaches – such as administering high doses of radiation therapy to the ovaries, surgically removing the ovaries, and removing the adrenal glands (which produce estrogen and other hormones) – can delay cancer recurrence and often extend the lives of women with breast cancer who have undergone mastectomy.

Doctors now know that about 75 percent of breast tumors are fueled by the hormones estrogen and progesterone. Instead of surgery or radiation, drugs such as goserelin (Zoladex), tamoxifen (Novaldex) and aromatase inhibitors are used to interfere with estrogen function or stop the production of these hormones. This approach carries far fewer risks and side effects than intensive radiation therapy or surgery.